Showing 20 of 45 recruiting trials for “mixed-phenotype-acute-leukemia-with-tv11q233”
A Study of Revumenib and Mezigdomide in People With Leukemia
👨⚕️ Eytan Stein, MD, Memorial Sloan Kettering Cancer Center📍 10 sites📅 Started Jan 2026View details ↗
Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
👨⚕️ Anna Halpern, MD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Oct 2025View details ↗
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
👨⚕️ Filippo Milano, MD, PhD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Sep 2025View details ↗
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
👨⚕️ Naveed Ali, MD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Sep 2025View details ↗
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
👨⚕️ Qiubai Li, Professor, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology📍 1 site📅 Started Feb 2025View details ↗
RecruitingNCT06452732 ↗
Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML
RecruitingNCT06458257 ↗
The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia
RecruitingNCT06458244 ↗
The Efficacy of Allo-HSCT in ND HR-CBF-AML
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
👨⚕️ Ann Dahlberg, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Jul 2024View details ↗
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
👨⚕️ Alice S Mims, Ohio State University Comprehensive Cancer Center LAO📍 22 sites📅 Started Jun 2024View details ↗
PTCy and ATG for MSD and MUD Transplants
👨⚕️ Leonardo J Arcuri, MD, PhD, Instituto Nacional de Cancer📍 1 site📅 Started Jun 2024View details ↗
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
👨⚕️ Xiaojun Huang, Doctor, Peking University People's Hospital📍 53 sites📅 Started Apr 2024View details ↗
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
👨⚕️ Uma M Borate, MD, MS, Ohio State University Comprehensive Cancer Center📍 3 sites📅 Started Feb 2024View details ↗
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
👨⚕️ Jacob Appelbaum, MD, PhD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Dec 2023View details ↗
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Page 1 of 3Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →